Dr Alastair Hick

Dr Alastair Hick is the inaugural Chief Commercialisation Officer at Monash University where he has been responsible for developing and overseeing the successful IP commercialisation program.

The IP commercialisation program included many different interventions including proof of concept and investment funds and strategic partnerships with multiple investors and corporate licensing partners. He also oversees The Generator, which runs a wide range of entrepreneurship programs across Monash with the objective of developing entrepreneurial talent.

He was the Chair of Knowledge Commercialisation Australasia from 2015-2018, on the Board from 2009-2018, and became a Life Member in 2020 and was awarded Technology Transfer Professional of the Year in 2023. He has developed and run multiple training programs for technology transfer professionals across Australia. He currently is a member of the NHMRC Health Research Impact Committee and the Hudson Institute of Medical Research IP Committee.

Alastair has a BSc (Hons) in Chemistry with Biochemistry, a PhD in Chemical Ecology, an MBA from the Judge Business School at the University of Cambridge, and is a Graduate of the Australian Institute of Company Directors. He is a Director of Monash spinouts Jupiter Ionics, Phrenix Therapeutics, Myostellar and Flex Immunotherapeutics as well as VC investor Uniseed. He was previously a Director of Amaero International prior to its IPO in late 2019 and was a founding Director of the $30M Trans-Tasman Commercialisation Fund, and a member of its investment committee.

Return to Our Board